
The Hunt For Mysterious 'Planet Nine' Offers Up A Surprise
It's an evocative idea that has long bedevilled scientists: a huge and mysterious planet is lurking in the darkness at the edge of our solar system, evading all our efforts to spot it.
Some astronomers say the strange, clustered orbits of icy rocks beyond Neptune indicate that something big is out there, which they have dubbed Planet Nine.
Now, a US-based trio hunting this elusive world has instead stumbled on what appears to be a new dwarf planet in the solar system's outer reaches.
And the existence of this new kid on the block could challenge the Planet Nine theory, the researchers have calculated.
Named 2017 OF201, the new object is roughly 700 kilometres (430 miles) across according to a preprint study, which has not been peer-reviewed, published online last week.
That makes it three times smaller than Pluto.
But that is still big enough to be considered a dwarf planet, lead study author Sihao Cheng of New Jersey's Institute for Advanced Study told AFP.
The object is currently three times farther away from Earth than Neptune.
And its extremely elongated orbit swings out more than 1,600 times the distance between the Earth and the Sun, taking it into the ring of icy rocks around the solar system called the Oort cloud.
It goes so far out, it could have passed by stars other than our Sun in the past, Cheng said.
During its 25,000-year orbit, the object is only close enough to Earth to be observed around 0.5 percent of the time, which is roughly a century.
"It's already getting fainter and fainter," Cheng said.
The discovery suggests "there are many hundreds of similar things on similar orbits" in the Kuiper Belt beyond Neptune, Cheng said.
After taking a risk spending more than half a year sorting through a difficult dataset in search of Planet Nine, Cheng said he was "lucky" to have found anything at all.
The researchers are requesting time to point the James Webb, Hubble and ALMA telescopes at their discovery.
But Sam Deen, a 23-year-old amateur astronomer from California, has already been able to track the dwarf planet candidate through old datasets.
"OF201 is, in my opinion, probably one of the most interesting discoveries in the outer solar system in the last decade," Deen told AFP.
The icy rocks discovered in the Kuiper belt tend to have a clustered orbit going in a particular direction.
Two decades ago, astronomers proposed this was due to the gravitational pull of a world up to 10 times larger than Earth, naming it Planet Nine and kicking off a debate that has rumbled since.
It is also sometimes called Planet X, a name proposed for a hypothetical world beyond Neptune more than a century ago.
Back in 1930, astronomers were searching for Planet X when they discovered Pluto, which became our solar system's ninth planet.
But Pluto turned out to be too tiny -- it is smaller than the Moon -- and was demoted to dwarf planet status in 2006.
There are now four other officially recognised dwarf planets, and Cheng believes 2017 OF201 could join their ranks.
When the researchers modelled its orbit, they found it did not follow the clustered trend of similar objects.
This could pose a problem for the Planet Nine theory, but Cheng emphasised more data is needed.
Samantha Lawler of Canada's University of Regina told AFP that this "great discovery" and others like it mean that "the original argument for Planet Nine is getting weaker and weaker".
The Vera Rubin Observatory, which is scheduled to go online in Chile this year, is expected to shed light on this mystery, one way or another.
Deen said it was discouraging that no sign of Planet Nine has been found so far, but with Vera Rubin "on the horizon I don't think we'll have to wonder about its existence for much longer".
For Cheng, he still hopes that this huge planet is out there somewhere.
"We're in an era when big telescopes can see almost to the edge of the universe," he said.
But what is in our "backyard" still largely remains unknown, he added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


DW
11 hours ago
- DW
Japan's ispace fails second lunar landing mission – DW – 06/06/2025
Japanese startup failed to land its unmanned Resilience craft on the moon. The mission was aborted as it was likely the craft had crashed after losing contact. Japan'sprivate moon mission was aborted on Friday after it was presumed that the unmanned Resilience spacecraft had crashed. Tokyo-based startup ispace had launched the mission in hopes of becoming the first private company outside the United States to achieve a controlled lunar landing. Lunar lander crashed into moon The Resilience spacecraft had begun its final descent, successfully firing its main engine "as planned to begin deceleration," ispace said. Mission control reported that the craft's position was "nearly vertical," but contact was then lost. ispace stated that the spacecraft had likely failed to decelerate sufficiently to reach the speed required for a soft lunar landing. "Based on the currently available data... it is currently assumed that the lander likely performed a hard landing. It is unlikely that communication with the lander will be restored, so it has been decided to conclude the mission," ispace said in a statement. Before signing off, the livestream announcers said, "never quit the lunar quest." A new time: Clocks on the moon To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Less than two minutes before the scheduled landing, the once-celebratory gathering of 500 ispace employees, shareholders, sponsors, and government officials fell into stunned silence as contact with the spacecraft was lost. ispace had also organized a public viewing event. Image: Manami Yamada/REUTERS "Expectations for ispace will not waver," Japanese Prime Minister Shigeru Ishiba posted on X. Second failed attempt Two years ago, another lunar missionby the company had also ended in a crash. CEO Takeshi Hakamada told reporters he took the second failed attempt "seriously" and intended to use the outcome to inform future missions. He said they had a "strong will to move on, although we have to carefully analyze what happened." Resilience carried a four-wheeled rover built by ispace's Luxembourg subsidiary, along with five external payloads valued at a total of $16 million. The planned landing site was Mare Frigoris, a plain about 900 km (560 miles) from the moon's north pole. Lunar landings remain challenging due to the moon's rugged terrain. To date, only five nations have successfully achieved soft lunar landings: Russia, US, China, India and Japan. Private companies have recently entered the race to the moon, and ispace would have been the third such company to achieve it. The mission wanted to collect two lunar soil samples and sell them to NASA for $5,000 (€4373). In January, Resilience shared a SpaceX rocket launch with Firefly's Blue Ghost lander, which touched down successfully in March. A moon landing attempt by US-based company Intuitive Machines failed in March this year. IDEFIX rover and JAXA's mission to the moons of Mars To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Edited by: Louis Oelofse


Int'l Business Times
5 days ago
- Int'l Business Times
Saudi Arabia Advances Cancer Care with Potential Approval of Multikine Immunotherapy
In a pivotal development in cancer care, Saudi Arabia may become the first country in the world to approve CEL-SCI Corporation 's investigational immunotherapy, Multikine, for commercial use in treating head and neck cancer. The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine available to patients as early as this summer. This move comes after favorable engagement between CEL-SCI and SFDA reviewers announced in April of this year, positioning Saudi Arabia at the forefront of global innovation in oncology. If approved, Multikine would represent a new era in immuno-oncology by becoming the first neoadjuvant (pre-surgical) immunotherapy available for advanced primary head and neck cancer. The Unmet Need in Head and Neck Cancer Head and neck cancers (HNCs) account for 5% of all cancer cases in Saudi Arabia, which is around 650–700 new cases every year. Mostly affecting men attributed to tobacco use, including cigarettes, shisha, and smokeless tobacco like shamma . In the southern provinces like Jazan, shamma use is linked to high oral cancer rates, including among women. Head and neck cancers are often diagnosed at advanced stages, with 80% or more of patients having lymph node involvement at diagnosis. The most common subtypes in the Kingdom are oral cavity and nasopharyngeal carcinomas. Despite advances in surgery and radiation, 5-year survival rates have plateaued at 50%, so there is a big need for more effective first-line treatment options. The Science Behind Multikine Multikine (Leukocyte Interleukin, Injection) is a unique immunotherapeutic biologic composed of a carefully calibrated mix of natural cytokines derived from activated human white blood cells. Unlike checkpoint inhibitors used in later-stage cancers, Multikine is designed to be administered before surgery, while the patient's immune system is still intact and the tumor is present as a target. In CEL-SCI's global Phase III trial , the largest ever conducted in head and neck cancer, Multikine demonstrated a statistically significant improvement in five-year survival rates for a defined patient subgroup: those treated with surgery followed by radiation but not chemotherapy. Among these patients, five-year survival improved from 48.6% to 62.7%, effectively cutting the risk of death nearly in half. Multikine also showed strong safety results, with no late toxicities reported and notable improvements in patient-reported quality of life. Some patients experienced complete tumor regression before surgery, supporting the idea that Multikine may sensitize tumors to subsequent standard treatments. Alignment with Saudi Vision 2030 The approval of Multikine fits perfectly into Saudi Vision 2030 , the national framework for economic diversification and innovation that includes transforming the healthcare and biotech sectors. Central to this transformation is the localization of pharmaceutical manufacturing, attracting clinical research, and becoming a regional hub for medical innovation. The SFDA's Breakthrough Medicine Designation, modeled after similar programs in the U.S. and EU, is a direct byproduct of this strategy. It aims to expedite the approval of therapies that show significant clinical promise in addressing unmet medical needs. By targeting a cancer type with limited first-line advancements, Multikine qualifies as a prime candidate for such accelerated evaluation. Saudi Arabia has also shown leadership in adopting advanced oncology treatments. The country recently became the first in the region to manufacture CAR-T cell therapies domestically, reducing costs and access times for blood cancer patients. The addition of Multikine would continue this trend of delivering next-generation therapeutics within the Kingdom. Oncology Infrastructure Ready for Innovation Saudi Arabia's oncology infrastructure has matured significantly over the last decade. Institutions like King Faisal Specialist Hospital & Research Centre (KFSHRC), King Fahad Medical City (KFMC), and Princess Noorah Oncology Center are now equipped with the latest technologies, including proton therapy and precision diagnostics. These institutions routinely adopt new cancer treatments and maintain specialized head and neck cancer teams composed of ENT surgeons, radiation oncologists, medical oncologists, and rehabilitation professionals. The availability of multidisciplinary tumor boards and growing use of tele-oncology services further support the clinical integration of innovative therapies like Multikine. The Ministry of Health's e-Platform for oncology consultations ensures that even patients in remote regions can access national expertise, which is an essential element as the country decentralizes specialist care under the Vision 2030 framework. Regional and Global Impact If Saudi Arabia approves Multikine in 2025, it will not only be a therapeutic breakthrough for patients but also a model for fast-tracking drug development in the MENA region. CEL-SCI has already announced plans to partner with a local manufacturer in the Kingdom to supply Multikine across the Middle East and North Africa. The implications go beyond geography. An early Saudi approval will strengthen CEL-SCI's case for conditional approvals in other jurisdictions, including Canada and the EU, where the company has filed parallel regulatory submissions. What's Ahead Multikine's journey of over a decade of clinical development is the potential of immunotherapy to improve survival in areas where there are few options. Saudi Arabia's regulatory and clinical leadership may now be the launchpad for this innovation. For patients newly diagnosed with head and neck cancer in the Kingdom, this means more than hope. It soon means potential access.


Int'l Business Times
30-05-2025
- Int'l Business Times
Abortion Pill Inventor Etienne-Emile Baulieu Dies Aged 98
French scientist Etienne-Emile Baulieu, known as the inventor of the abortion pill, died at the age of 98 at his home in Paris on Friday, his wife told AFP. The doctor and researcher, who achieved worldwide renown for his work that led to the pill, had an eventful life that included fighting in the French resistance and becoming friends with artists such as Andy Warhol. "His research was guided by his commitment to the progress made possible by science, his dedication to women's freedom, and his desire to enable everyone to live better, longer lives," Baulieu's wife Simone Harari Baulieu said in a statement. Baulieu's most well-known discovery helped create the oral drug RU-486, also known as mifepristone, which provided a safe and inexpensive alternative to surgical abortion to millions of women across the world. His work meant he also faced fierce criticism and sometimes threats from opponents of abortion. After Wyoming became the first US state to outlaw the use of the abortion pill in 2023, Baulieu told AFP it was "scandalous". Baulieu said he had dedicated a large part of his life to "increasing the freedom of women," and the ban was a step in the opposite direction. Born on December 12, 1926 in Strasbourg to Jewish parents, Etienne Blum was raised by his feminist mother after his father, a doctor, died. He changed his name to Emile Baulieu when he joined the French resistance against Nazi occupation at the age of 15, then later adding Etienne. After the war, he became a self-described "doctor who does science," specialising in the field of steroid hormones. Invited to work in the United States, Baulieu was noticed in 1961 by Gregory Pincus, known as the father of the contraceptive pill, who convinced him to focus on sex hormones. Back in France, Baulieu designed a way to block the effect of the hormone progesterone, which is essential for the egg to implant in the uterus after fertilisation. This led to the development of mifepristone in 1982. In the 1960s, the literature fan had become friends with artists such as Andy Warhol. He said he was "fascinated by artists who claim to have access to the human soul, something that will forever remain beyond the reach of scientists." Baulieu kept going into Parisian office into his mid-90s. "I would be bored if I did not work anymore," he said in 2023. His recent research has included trying to find a way to prevent the development of Alzheimer's disease, as well as a treatment for severe depression, for which clinical trials are currently underway across the world. French President Emmanuel Macron presented Baulieu with the Grand-Croix de la Legion d'Honneur in 2023, the top rank in France's honours system. "You, a Jew and a resistance fighter, you were overwhelmed with the most atrocious insults and even compared to Nazi scientists," Macron said. "But you held on, for the love of freedom and science." In the United States, Baulieu was also awarded the prestigious Lasker prize in 1989. The widower of Yolande Compagnon, Baulieu married Simone Harari in 2016. He leaves behind three children, eight grandchildren and nine great-grandchildren, according to the statement released by his family.